Printer Friendly

Cosmeceutical critique: Portulaca oleracea (purslane).

Portulaca oleracea, also known as purslane, has long been used in various traditional medicine systems to relieve pain and edema. (1) Portulaca oleracea is a warm-climate annual plant originally found in the Middle East, North Africa, and the Indian subcontinent and now cultivated in the Arabian peninsula; Japan, where it is an abundant garden plant from spring to fall (2,3); and throughout the world.

The use of P. oleracea, a member of the Portulacaceae family, as a vegetable as well as herbal medicine dates back several centuries. (4) In modern times, purslane has been found to be rich in antioxidants, particularly omega-3 fatty acids, vitamins C and E, beta-carotene, melatonin, and glutathione, as well as several minerals. (5-7) Currently, it is considered one of the top 10 most common plants in the world, and one of the most-used medical plants according to the World Health Organization. (6)

Antioxidant activity

Using two different assays, Uddin et al. determined in 2012 that P. oleracea cultivars exhibited significant antioxidant activity through various growth stages. In addition, the researchers suggested that purslane could provide multiple minerals as well as antioxidants in the context of nutraceutical products and functional food. (7) Early this year, Silva et al. studied the antioxidant activity of P. oleracea leaves, flowers, and stems from two different locations in Portugal, with assays revealing significantly greater antioxidant activity in the stems of both samples compared to the leaves and flowers. However, the phenolic extracts of all three plant sections from both samples were found to protect DNA against hydroxyl radicals. (8)

A 2014 analysis of 13 collected purs-lane accessions revealed significant mineral content (particularly potassium, followed by nitrogen, sodium, calcium, magnesium, phosphorus, iron, zinc, and manganese) and showed that antioxidant activity was more strongly associated with ornamental as opposed to common purslane. (6)

Anti-inflammatory activity

In 2000, Chan et al. found that a 10% ethanolic extract of the dried leaves and stem of a P oleracea cultivar displayed significant anti-inflammatory and analgesic properties after topical and intraperitoneal, but not oral, administration in comparison to diclofenac sodium, a synthetic drug used as active control. (9)

Wound healing activity

Rashed et al. reported in 2003 that a crude extract of P. oleracea accelerates wound healing. They used Mus musculus JVI-1 to show that fresh homogenized crude aerial parts of the plant topically applied on excision wound surfaces reduced wound surface areas and increased tensile strength. The best documented contraction was associated with a single dose of 50 mg, followed by two doses of 25 mg each. (10)

Oral lichen planus treatment

In 2010, Agha-Hosseini et al. conducted a randomized double-blind placebo-controlled 3-month study to assess the effectiveness of purslane in the treatment of oral lichen planus. Thirty-seven symptomatic patients (confirmed by biopsy) were divided into a purslane treatment group (n = 20) and a placebo group (n = 17). The investigators reported that partial to complete clinical improvement was observed in 83% of the treatment group, with no response in the remaining 17%, whereas partial improvement was seen in 17% of the placebo group, 73% had no response, and the condition was aggravated in 10% of the placebo group. (5)

Other activities

In 2001, Radhakrishnan et al. identified several neuropharmacological actions, particularly antinociceptive and muscle-relaxing activity, with a range of effects on the central and peripheral nervous system observed in animal studies.1 The betacyanins found in P. oleracea have subsequently been found to confer a protective effect against neurotoxicity, specifically, ameliorating the D-galactose-induced cognitive deficits in senescent mice. (11) P. oleracea also has been shown to eliminate the endocrine-disrupting chemical bisphenol A from a hydroponic solution. (12)

In 2012, Yan et al. showed that three newly isolated homoisoflavonoids, known as portulacanones, and the compound 2,2'-dihydroxy-4',6'-dimethoxychalcone selectively exhibited in vitro cytotoxic activities against four human cancer cell lines. (2)


This antioxidant-rich plant is found throughout the world and has long been associated with traditional health care. There are indications that the antioxidant, anti-inflammatory, and wound healing activity reportedly exhibited by purslane may be harnessed for various cutaneous applications. However, much more research is necessary to determine how extensive a role purslane may play in skin care.



(1.) J. Ethnopharmacol. 2001;76:171-6.

(2.) Phytochemistry 2012;80:37-41.

(3.) J. Biosci. Bioeng. 2007;103:420-6.

(4.) J. Ethnopharmacol. 2000;73:445-51.

(5.) Phytother. Res. 2010;24:240-4.

(6.) Biomed. Res. Int. 2014;2014:296063.

(7.) Int. J. Mol. Sci. 2012;13:10257-67.

(8.) Nat. Prod. Commun. 2014;9:45-50.

(9.) J. Ethnopharmacol. 2000;73:445-51.

(10.) J. Ethnopharmacol. 2003;88:131-6.

(11.) Phytomedicine 2010;17:527-32.

(12.) Biosci. Biotechnol. Biochem. 2012;76:1015-7.

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in the Design District in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann wrote the textbook "Cosmetic Dermatology: Principles and Practice" (New York: McGraw-Hill, 2002), and a book for consumers, "The Skin Type Solution" (New York: Bantam Dell, 2006). She has contributed to the Cosmeceutical Critique column in Dermatology News since January 2001. Her latest book, "Cosmeceuticals and Cosmetic Ingredients, " was published in November 2014. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Evolus, Galderma, GlaxoSmithKline, Kythera Biopharmaceuticals, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Topix Pharmaceuticals, and Unilever.


Please note: Illustration(s) are not available due to copyright restrictions.
COPYRIGHT 2015 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Baumann, Leslie S.
Publication:Dermatology News
Date:Jun 1, 2015
Previous Article:Sun protection and aesthetic procedures.
Next Article:Skin patch aids Q-switched laser tattoo removal.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters